LILRB1 and B-cell chronic lymphocytic leukemia: Moreover, LIR‐1 blockade improves chronic lymphocytic leukaemia targeting by lenalidomide‐exposed NK cells38 and triggers NK cell cytotoxicity against primary leukaemic blasts.26